Clinical trials

  • PIVMECILLINAM HYDROCHLORIDE for Complicated urinary tract infection (cUTI)
  • PIT565 for Systemic lupus erythematosus
  • BINIMETINIB for Melanoma with brain metastases (BRAF V600 mutation-positive)
  • NNC9733-0001 for Type 2 diabetes
  • RMC-6291 for Non-small cell lung cancer|RAS G12C-mutated non-small cell lung cancer
  • Treprostinil sodium for Pulmonary arterial hypertension
  • MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE for Primary myelofibrosis | Post-polycythaemia vera myelofibrosis | Post-essential thrombocythaemia myelofibrosis
  • Synthetic double-stranded siRNA oligonucleotide directed against apolipoprotein C-III mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues for Hypertriglyceridemia
  • TOLEBRUTINIB for Relapsing multiple sclerosis | Primary progressive multiple sclerosis | Secondary progressive multiple sclerosis
  • SULODEXIDE for Venous thromboembolism (deep vein thrombosis and pulmonary embolism) | Deep vein thrombosis | Pulmonary embolism
  • ALPELISIB for Hormone receptor-positive HER2-negative advanced breast cancer
  • surovatamig for Rheumatoid arthritis|Systemic lupus erythematosus